Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Trends: Merck & Co Insider Converts Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact

05/04/2021 | 05:04pm EDT


© MT Newswires 2021
All news about MERCK & CO., INC.
05/10ALX ONCOLOGY  : Doses First Patient in Phase 2 Study of ALX148 in Combination Wi..
MT
05/07MERCK  : to Spin Off Organon Women's Health Unit to Shareholders on June 2
MT
05/07MERCK  : Declares Record Date and Dividend for the Organon & Co. Spinoff
BU
05/07EISAI  : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review..
AQ
05/06INSIDER TRENDS : Merck & Co Insider Converts Option/Derivative Security Sells Po..
MT
05/06INSIDER TRENDS : Insider at Merck & Co Acquires Stock Via Conversion of Option/D..
MT
05/06MERCK  : Notice to Directors and Executive Officers, dated May 5, 2021
PU
05/06FUSION PHARMACEUTICALS  : Partners With Merck Unit For Clinical Tria Collaborati..
MT
05/06MERCK  : Eisai Receive US FDA Priority Review for Cancer Drug Candidates Keytrud..
MT
05/06MERCK  : FDA Approves Merck's KEYTRUDA (pembrolizumab) Combined With Trastuzumab..
AQ
More news
Financials (USD)
Sales 2021 51 892 M - -
Net income 2021 14 041 M - -
Net Debt 2021 19 284 M - -
P/E ratio 2021 14,4x
Yield 2021 3,33%
Capitalization 196 B 196 B -
EV / Sales 2021 4,15x
EV / Sales 2022 3,81x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,90 $
Last Close Price 77,46 $
Spread / Highest target 39,4%
Spread / Average Target 22,5%
Spread / Lowest Target -0,59%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-5.31%196 133
JOHNSON & JOHNSON7.31%444 728
ROCHE HOLDING AG-3.32%285 850
PFIZER, INC.8.29%219 501
ABBVIE INC.7.22%202 921
NOVARTIS AG-5.65%196 492